Jul 12, 2018   SOURCE: PR NewsWire

Global Fibromyalgia Therapeutics Strategic Business Report 2018: Annual Estimates & Forecasts (2015-2022)

DUBLIN, July 12, 2018 /PRNewswire/ --

The "Fibromyalgia Therapeutics - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.

http://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for this market. The report analyzes the Global market for Fibromyalgia Therapeutics in US$ Million.

The report profiles 22 companies including many key and niche players such as:

    --  Allergan plc (Ireland)
    --  Boehringer Ingelheim GmbH (Germany)
    --  Daiichi Sankyo Company Limited (Japan)
    --  Eli Lilly and Company (USA)
    --  Innovative Med Concepts, Inc. (USA)
    --  Pfizer, Inc. (USA)
    --  Pierre Fabre Mdicament (France)
    --  SWITCHBIOTECH LLC (USA)
    --  Zynerba Pharmaceuticals, Inc. (USA)

Key Topics Covered

1. INDUSTRY OVERVIEW
Fibromyalgia Syndrome: A Prelude
Fibromyalgia Therapeutics Market: A Nascent Sector
A Glance at the Current & Future Fibromyalgia Therapeutics Portfolio
FDA Approved Fibromyalgia Drugs
IMC-1: A Revolutionary Combination Therapy
Daiichi Sankyo's Mirogabalin Drug Improvises on Lyrica
Tonix Pharma Develops Newer Sublingual Formulation of Cyclobenzaprine
Understanding Heightened Effect of Pain in Women Due to Fibromyalgia
Inconsistencies and Loopholes in Current Fibromyalgia Diagnoses
Fibromyalgia Treatment through High-Pressure Oxygen Application
EU approves New Device to Treat Fibromyalgia and Migraine

2. AVAILABLE & PIPELINE FIBROMYALGIA DRUGS
AN OVERVIEW
Medications Used in the Fibromyalgia Treatment
Pain Relievers
Antidepressants
Anti-Seizure Drugs
Medication for Improving Sleep
Muscle Relaxants
Antipsychotics
A Glance at Available Fibromyalgia Drugs
Lyrica (pregabalin)
Cymbalta (duloxetine HCl)
Savella (milnacipran HCl)
Fibromyalgia Products in Pipeline
Mirogabalin
IMC-1
SWT06101

3. FIBROMYALGIA
THE DISEASE, SYMPTOMS, AND DIAGNOSIS

4. MANAGEMENT OF FIBROMYALGIA
Non-Pharmacological Treatment of Fibromyalgia
Nutritional Therapy
Exercise
Cognitive Behavior Therapy
Pharmacological Treatment Alternatives for Fibromyalgia
Antidepressants
Tricyclic Antidepressants (TCA)
Dopamine Agonists
Muscle Relaxants
Selective Serotonin-Norephinephrine Inhibitors (SNRIs)
Selective Serotonin Reuptake Inhibitors (SSRIs)
Drug Therapy for Fibromyalgia-Related Fatigue
Other Therapeutic Agents for Fibromyalgia Treatment
Conclusion

5. CLINICAL STUDIES & PRODUCT LAUNCHES/APPROVALS
Cannabis Science Introduces Fibromyalgia Pain Relief Medication
Soterix Medical Launches PainX tDCS Treatment in Canada
Synovation Medical Group to Conduct Study on NeuroMetrix's Quell Wearable Pain Relief Technology
FDA Grants Fast Track Designation to Innovative Med Concepts' IMC-1
Soterix Medical's PainX Treatment Receives CE Mark Approval
Tonix Pharmaceuticals Begins Phase 3 Trial of TNX-102 SL
Pfizer's Lyrica Fails to Meet FDA Requirements in Post- Marketing Study
Premier Biomedical to Submit Application to FDA for Fibromyalgia Therapy

6. FOCUS ON SELECT GLOBAL PLAYERS
Allergan plc (Ireland)
Boehringer Ingelheim GmbH (Germany)
Daiichi Sankyo Company Limited (Japan)
Eli Lilly and Company (USA)
Innovative Med Concepts, Inc. (USA)
Pfizer, Inc. (USA)
Pierre Fabre Mdicament (France)
SWITCHBIOTECH LLC (USA)
Zynerba Pharmaceuticals, Inc. (USA)

7. GLOBAL MARKET PERSPECTIVE

Total Companies Profiled: 22 (including Divisions/Subsidiaries 23) 

    --  The United States (12)
    --  Canada (1)
    --  Japan (4)
    --  Europe (5)
        --  France (1)
        --  Germany (1)
        --  Rest of Europe (3)
    --  Asia-Pacific (Excluding Japan) (1)

For more information about this report visit https://www.researchandmarkets.com/research/h2dpck/global?w=5

Did you know that we also offer Custom Research? Visit our Custom Research page to learn more and schedule a meeting with our Custom Research Manager.

Media Contact:

Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/global-fibromyalgia-therapeutics-strategic-business-report-2018-annual-estimates--forecasts-2015-2022-300680290.html

SOURCE Research and Markets